BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34649021)

  • 21. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-A case report.
    Jarmoliński T; Matkowska-Kocjan A; Rosa M; Olejnik I; Gorczyńska E; Kałwak K; Ussowicz M
    Pediatr Transplant; 2021 Aug; 25(5):e13875. PubMed ID: 32949079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey.
    Passweg JR; Baldomero H; Chabannon C; Corbacioglu S; de la Cámara R; Dolstra H; Glass B; Greco R; Mohty M; Neven B; Peffault de Latour R; Perić Z; Snowden JA; Yakoub-Agha I; Sureda A; Kröger N;
    Bone Marrow Transplant; 2022 May; 57(5):742-752. PubMed ID: 35194156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
    Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
    J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
    Ali H; Ngo D; Aribi A; Arslan S; Dadwal S; Marcucci G; Nakamura R; Forman SJ; Chen J; Al Malki MM
    Transplant Cell Ther; 2021 Nov; 27(11):938.e1-938.e6. PubMed ID: 34274492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey.
    Passweg JR; Baldomero H; Ciceri F; Corbacioglu S; de la Cámara R; Dolstra H; Glass B; Greco R; McLornan DP; Neven B; de Latour RP; Perić Z; Ruggeri A; Snowden JA; Sureda A
    Bone Marrow Transplant; 2023 Jun; 58(6):647-658. PubMed ID: 36879108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance Strategies After Hematopoietic Cell Transplantation.
    Culos KA; Gatwood KS; Byrne M
    Pharmacotherapy; 2020 Aug; 40(8):727-740. PubMed ID: 32343426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group.
    Schaffrath J; Brummer C; Wolff D; Holtick U; Kröger N; Bornhäuser M; Kraus S; Hilgendorf I; Blau IW; Penack O; Wittke C; Steiner N; Nachbaur D; Thurner L; Hindahl H; Zeiser R; Maier CP; Bethge W; Müller LP
    Transplant Cell Ther; 2022 Jun; 28(6):337.e1-337.e10. PubMed ID: 35296445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T Cell Therapy Recipients with Pre-Cellular Therapy SARS-CoV-2 Infection.
    Nimgaonkar I; Yoke LH; Roychoudhury P; Flaherty PW; Oshima MU; Weixler A; Gauthier J; Greninger AL; Mielcarek M; Boeckh M; Liu C; Hill JA
    Clin Infect Dis; 2024 Mar; ():. PubMed ID: 38427848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma.
    Ida H; Inamoto Y; Fukuhara S; Maeshima AM; Takeda W; Hirakawa T; Kuno M; Aoki J; Tanaka T; Ito A; Kim SW; Izutsu K; Fukuda T
    Hematol Oncol; 2021 Dec; 39(5):650-657. PubMed ID: 34431557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Acute Promyelocytic Leukemia.
    Yanada M; Matsuda K; Ishii H; Fukuda T; Ozeki K; Ota S; Tashiro H; Uchida N; Kako S; Doki N; Kawakita T; Onishi Y; Takada S; Kondo Y; Tanaka J; Kanda Y; Atsuta Y; Yano S
    Transplant Cell Ther; 2022 Dec; 28(12):847.e1-847.e8. PubMed ID: 36179987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
    Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19.
    Lázaro Del Campo P; de Paz Arias R; Ramírez López A; de la Cruz Benito B; Humala Barbier K; Sánchez Vadillo I; López de la Guía A; de Soto Álvarez T; Jiménez Yuste V; Canales Albendea M
    Transfus Apher Sci; 2020 Dec; 59(6):102921. PubMed ID: 32928663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of COVID-19 on patients treated with autologous hematopoietic stem cell transplantation: A retrospective cohort study.
    Silfverberg T; Wahlin B; Carlson K; Cherif H
    Ups J Med Sci; 2022; 127():. PubMed ID: 36120088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
    Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
    Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    Clin Infect Dis; 2024 May; ():. PubMed ID: 38801746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation.
    Worel N; Shaw BE; Aljurf M; Koh M; Seber A; Weisdorf D; Schwartz J; Galeano S; Kodera Y; Eldridge PW; Hashmi S; Atsuta Y; Szer J; Saber W; Niederwieser D; Greinix HT;
    Transplant Cell Ther; 2021 Mar; 27(3):270.e1-270.e6. PubMed ID: 33781537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves.
    Nawas MT; Shah GL; Feldman DR; Ruiz JD; Robilotti EV; Aslam AA; Dundas M; Kamboj M; Barker JN; Cho C; Chung DJ; Dahi PB; Giralt SA; Gyurkocza B; Lahoud OB; Landau HJ; Lin RJ; Mailankody S; Palomba ML; Papadopoulos EB; Politikos I; Ponce DM; Sauter CS; Shaffer BC; Scordo M; van den Brink MRM; Perales MA; Tamari R
    Transplant Cell Ther; 2021 May; 27(5):438.e1-438.e6. PubMed ID: 33728417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.